Investigation of the Effect of KIR–HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients

Takeji Umemura 1,2,3,*; Satoru Joshita 4; Hiromi Saito 1; Shun-ichi Wakabayashi 1; Hiroyuki Kobayashi 1; Yuki Yamashita 1, Ayumi Sugiura 1,2; Tomoo Yamazaki 1 and Masao Ota 1,2

1 Department of Medicine, Division of Gastroenterology and Hepatology, Shinshu University School of Medicine, Matsumoto 390-8621, Nagano, Japan; joshita@shinshu-u.ac.jp (S.J.); hiropon@shinshu-u.ac.jp (H.S.); 20hm144@shinshu-u.ac.jp (S.-i.W.); 20hm116c@shinshu-u.ac.jp (H.K.); yukiyama@shinshu-u.ac.jp (Y.Y.); asugiura@shinshu-u.ac.jp (A.S.); ymzkm6@shinshu-u.ac.jp (T.Y.); otamasao@shinshu-u.ac.jp (M.O.)
2 Consultation Center for Liver Diseases, Shinshu University Hospital, Matsumoto 390-8621, Nagano, Japan
3 Department of Life Innovation, Shinshu University, Matsumoto 390-8621, Nagano, Japan
* Correspondence: tumemura@shinshu-u.ac.jp; Tel.: +81-263-37-2634; Fax: +81-263-32-9412

Citation: Umemura, T.; Joshita, S.; Saito, H.; Wakabayashi, S.-i.; Yamashita, Y.; Sugiura, A.; Yamazaki, T.; Ota, M. Investigation of the Effect of KIR–HLA Pairs on Hepatocellular Carcinoma in Hepatitis C Virus Cirrhotic Patients. Cancers 2021, 13, 3267. https://doi.org/10.3390/cancers13133267

Received: 20 April 2021; Accepted: 25 June 2021; Published: 29 June 2021

Abstract: Natural killer (NK) cells normally respond to tumor cells and virally infected cells by killing them via the innate immune system. However, the functional impairment of NK cells has been observed in hepatocellular carcinoma. The NK-cell phenotype is partially mediated through the binding of killer cell immunoglobulin-like receptors (KIR) with human leukocyte antigen (HLA) class I ligands. This investigation examined the risk of hepatocellular carcinoma (HCC) in relation to KIR–HLA pairs in patients with compensated hepatitis C virus (HCV)-associated cirrhosis. A total of 211 Japanese compensated HCV cirrhotic cases were retrospectively enrolled. After KIR, HLA-A, HLA-Bw, and HLA-C typing, associations between HLA, KIR, and KIR–HLA combinations and HCC development were evaluated using the Cox proportional hazards model with the stepwise method. During a median follow-up period of 6.6 years, 69.7% of patients exhibited HCC. The proportions of HLA-Bw4 and the KIR3DL1 + HLA-Bw4 pair were significantly higher in patients with HCC than in those without (78.9% vs. 64.1%; odds ratio—2.05, 95% confidence interval (CI)—1.12–4.01; p = 0.023 and 76.2% vs. 60.9%, odds ratio—2.05, 95% CI—1.12–4.01; p = 0.023, respectively). Multivariate analysis revealed the factors of male gender (hazard ratio (HR)—2.10, 95% CI—1.10–4.01; p = 0.011), age ≥ 60 years (HR—1.56, 95% CI—1.12–2.17; p = 0.009), α-fetoprotein > 5.6 ng/mL (HR—1.56, 95% CI—1.12–2.10; p = 0.01), and KIR3DL1 + HLA-Bw4 (HR—1.69, 95% CI—1.15–2.48; p = 0.007) as independent risk factors for developing HCC. Furthermore, the cumulative incidence of HCC was significantly higher in patients with KIR3DL1 + HLA-Bw4 than in those without (log-rank test; p = 0.013). The above findings suggest KIR3DL1 + HLA-Bw4, in addition to HLA-Bw4, as a novel KIR–HLA pair possibly associated with HCC development in HCV cirrhosis. HCV-associated cirrhotic patients with the risk factors of male gender, α-fetoprotein > 5.6 ng/mL, and KIR3DL1 + HLA-Bw4 may require careful surveillance for HCC onset.

Keywords: cirrhosis; hepatitis C virus; hepatocellular carcinoma; human leukocyte antigen; killer cell immunoglobulin-like receptors; natural killer cells

1. Introduction

Chronic hepatitis C virus (HCV) infection is one of the major causes of cirrhosis and hepatocellular carcinoma (HCC) [1,2], the latter of which is prominently involved in cancer-
related death [3,4]. In Japan, HCV-related HCC accounts for approximately 60% of all HCC cases [5]. The mechanisms related to the progression of HCV infection to HCC include viral, environmental, and host genetic factors [6,7].

Natural killer (NK) cells are innate lymphocytes that are crucial for the early control of several pathogenic infections and malignancies [8]. NK cells express a wide repertoire of activating and inhibitory killer cell immunoglobulin-like receptors (KIR), which detect the expression levels of major histocompatibility complex class I ligands on normal and diseased cells in humans [9]. The expression of cognate human leukocyte antigen (HLA) class I molecules on target cells results in the inhibition of NK cell-mediated cytolysis via inhibitory KIR molecules, whereas the absence or aberrant presentation of these molecules leads to the activation of NK cells via KIR and other activating receptors [10]. KIR2DL1 recognizes HLA-C group 2 (HLA-C2) allotypes that share lysine at position 80, while KIR2DL2 and KIR2DL3 are specific for HLA-C group 1 (HLA-C1) allotypes having asparagine at position 80 [11]. KIR3DL1 binds with higher affinity to HLA-Bw4 molecules containing isoleucine at position 80 (Bw4-80I) than to HLA-Bw4 molecules with threonine at position 80 (Bw4-80T) [12]. Similar to HLA molecules, KIR is highly polymorphic, which profoundly influences KIR–HLA interactions. These structural complexities, as well as extensive gene homology, have resulted in poor coverage using genome-wide association study methods, making KIR understudied as a cancer susceptibility trait.

Gene content variability at the KIR locus has been investigated as a susceptibility trait in a variety of infectious and autoimmune diseases [10]. The interactions between independently segregating KIR and HLA genes on the biologic function of NK cells have also been described for melanoma [13,14]. We previously examined the role of KIR–HLA in HCV-related HCC in a cross-sectional study and revealed that KIR2DL1 + HLA-C1 was associated with younger onset (<65 years old) HCV-related HCC [15]. Other cross-sectional studies have demonstrated relationships between KIR–HLA and HCV-related HCC [16,17], although none have addressed the development of HCC in HCV patients over long-term follow-up. As cirrhosis is one of the strongest risk factors for HCC development [2], the present study investigated the risk of HCC based on KIR–HLA pairs in patients with compensated HCV-associated cirrhosis.

2. Results

2.1. Patient Characteristics

The cohort’s characteristics are summarized in Table 1. Median age was 64 years and 52% of subjects were male. The median follow-up period was 6.6 years (interquartile range: 4.1–10.0). HCV genotype 1 was detected in 180 (85.3%) patients and genotype 2 was identified in 22 (14.7%) patients. The Child–Pugh–Turcotte score was A in all subjects. Although 94 patients (44.5%) had been treated with interferon-based therapy, none achieved a sustained virological response (SVR). During the observation period, 147 (69.7%) of 211 patients exhibited HCC, with a 5-year cumulative incidence of 26.3% and a 10-year cumulative incidence of 69.7%. The HCC group had a significantly higher male ratio as compared with the non-HCC group. The a-fetoprotein (AFP) was significantly higher, while albumin, platelet count, and PT% were significantly lower in patients with HCC than in those without.

| Characteristic       | Total (n = 211) | Patients with Hepatocellular Carcinoma (HCC) (n = 147) | Patients without HCC (n = 64) | p-Value |
|----------------------|----------------|------------------------------------------------------|-------------------------------|---------|
| Age, y               | 64 (46–78)     | 63 (46–77)                                           | 65 (45–80)                    | 0.110   |
| Male, %              | 110 (52.1)     | 84 (57.1)                                            | 26 (40.6)                     | 0.027   |
| Body Mass Index      | 22.3 (17.6–29.8)| 22.2 (17.7–29.7)                                     | 22.6 (17.2–33.5)              | 0.417   |
Table 1. Cont.

| Characteristic                  | Total (n = 211) | Patients with Hepatocellular Carcinoma (HCC) (n = 147) | Patients without HCC (n = 64) | p-Value |
|--------------------------------|----------------|-------------------------------------------------------|------------------------------|---------|
| Albumin, g/dL                  | 3.8 (3.0–4.5)   | 3.8 (2.9–4.5)                                        | 4.1 (3.1–4.5)                | 0.009   |
| Bilirubin, mg/dL               | 0.9 (0.5–1.8)   | 0.9 (0.5–1.8)                                        | 0.9 (0.4–1.9)                | 0.532   |
| ALT, IU/L                      | 55 (20–200)     | 56 (21–209)                                          | 54 (17–201)                  | 0.177   |
| Platelet count, \times 10^9/L | 10.6 (4.8–21.6) | 10.2 (4.8–21.1)                                      | 12.0 (5.0–22.4)              | 0.033   |
| Prothrombin time %             | 84.7 (62.3–108.0)| 84.7 (58.4–104.9)                                   | 84.8 (67.9–113.1)            | 0.031   |
| α-fetoprotein, ng/mL           | 6.9 (1.5–41.8)  | 9.2 (1.8–44.3)                                       | 3.7 (1.2–30.8)               | <0.001  |
| Des-gamma-carboxy prothrombin, mAU/mL | 18.0 (9.5–40.0)      | 19.0 (9.2–40.9)                                      | 13.0 (8.2–37.6)              | 0.015   |
| HCV RNA, log IU/mL             | 6.5 (3.4–7.3)   | 6.5 (3.3–7.3)                                        | 6.4 (4.0–7.4)                | 0.838   |
| HCV genotype 1, n (%)          | 180 (85.3)      | 125 (85.0)                                           | 55 (85.9)                    | 0.865   |
| Interferon treatment, n (%)    | 94 (44.5)       | 67 (45.6)                                            | 27 (42.2)                    | 0.649   |

Parameters are presented as the median (5th–95th percentiles) for continuous variables and the total number (%) for categorical variables.

2.2. HLA and KIR Genotyping in Patients with HCV-Induced Cirrhosis

To clarify the impact of HLA–KIR pairs on HCC development, HLA-Bw and HLA-C were tested and KIR genes were genotyped, and their frequencies were compared between patients with and without HCC. The HLA-Bw4-positive rate was significantly higher in the HCC group than in the non-HCC group (78.9% vs. 64.1%; odds ratio (OR)—2.10, 95% confidence interval (CI)—1.10–4.01; p = 0.023). There were no remarkable differences between the groups for the frequencies of HLA-Bw6, HLA-C1, HLA-C2, or 14 KIR genes. HLA-Bw4 is segregated into Bw4-80I or Bw4-80T subtypes based on a dimorphism (isoleucine vs. threonine) at position 80. We observed a significant difference in the frequency of Bw4-80I positivity (p = 0.048), but not Bw4-80T positivity (p = 0.698), between the HCC and non-HCC groups (Table 2). No significant differences were detected for genotype A/A or genotype B/x between the groups (Table 2).

Table 2. Frequency of HLA-Bw4, -Bw6, -C1, -C2, killer cell immunoglobulin-like receptor (KIR) genes, and KIR genotypes in patients with and without hepatocellular carcinoma (HCC).

| Genetic Factor | Patients with HCC (n = 147) | Patients without HCC (n = 64) | Odds Ratio | 95% Confidence Interval | p-Value |
|----------------|------------------------------|-------------------------------|------------|-------------------------|---------|
| HLA-Bw4        | 116 (78.9)                   | 41 (64.1)                     | 2.10       | 1.10–4.01               | 0.023   |
| HLA-Bw4-80I    | 97 (66.0)                    | 33 (51.6)                     | 1.82       | 1.00–3.31               | 0.048   |
| HLA-Bw4-80T    | 31 (21.1)                    | 12 (18.8)                     | 1.16       | 0.55–2.43               | 0.698   |
| HLA-Bw6        | 132 (89.8)                   | 56 (87.5)                     | 1.26       | 0.50–3.13               | 0.623   |
| HLA-C1         | 145 (98.6)                   | 64 (100.0)                    | -          | -                       | 0.869   |
| HLA-C2         | 19 (12.9)                    | 8 (12.5)                      | 1.04       | 0.43–2.51               | 0.932   |
| KIR2DL1        | 147 (100.0)                  | 64 (100.0)                    | -          | -                       | -       |
| KIR2DL2        | 25 (17.0)                    | 7 (10.9)                      | 1.67       | 0.68–4.08               | 0.259   |
| KIR2DL3        | 147 (100.0)                  | 64 (100.0)                    | -          | -                       | -       |
| KIR2DL4        | 147 (100.0)                  | 64 (100.0)                    | -          | -                       | -       |
| KIR2DL5        | 58 (39.5)                    | 29 (45.3)                     | 0.79       | 0.43–1.42               | 0.427   |
| KIR2DS1        | 61 (41.5)                    | 28 (43.8)                     | 0.91       | 0.50–1.65               | 0.761   |
| KIR2DS2        | 23 (15.6)                    | 8 (12.5)                      | 1.30       | 0.53–3.08               | 0.553   |
| KIR2DS3        | 20 (13.6)                    | 12 (18.8)                     | 0.68       | 0.31–1.50               | 0.338   |
| KIR2DS4        | 138 (93.9)                   | 58 (90.6)                     | 1.59       | 0.54–4.66               | 0.398   |
| KIR2DS5        | 41 (27.9)                    | 19 (29.7)                     | 0.92       | 0.48–1.75               | 0.790   |
| KIR3DL1        | 138 (93.9)                   | 61 (95.3)                     | 0.75       | 0.20–2.88               | 0.679   |
| KIR3DL2        | 147 (100.0)                  | 64 (100.0)                    | -          | -                       | -       |
| KIR3DL3        | 147 (100.0)                  | 64 (100.0)                    | -          | -                       | -       |
| KIR3DS1        | 60 (40.8)                    | 29 (45.3)                     | 0.83       | 0.46–1.50               | 0.543   |
| Genotype A/A   | 72 (49.0)                    | 27 (42.2)                     | 1.32       | 0.73–2.38               | 0.363   |
| Genotype B/x   | 75 (51.0)                    | 37 (57.8)                     | 0.76       | 0.42–1.37               | 0.363   |

Parameters are presented as the total number (%).
Since KIR interacts with specific HLA class I molecules, we examined KIR–HLA combinations in the HCC and non-HCC groups (Table 3). The frequency of KIR3DL1 + HLA-Bw4 in the HCC group was 76.2% and significantly higher than the 60.9% observed in the non-HCC group (OR—2.05, 95% CI—1.09–3.85; \( p = 0.024 \), corrected \( p = 0.31 \)). Moreover, KIR3DL1 + HLA-Bw4-80I was significantly associated with HCC (63.9% vs. 48.4%; OR—1.89, 95% CI—1.04–3.42; \( p = 0.035 \)). No differences were detected in the frequencies of the other KIR–HLA pairs between the groups. Moreover, the frequency of genotype A/A did not differ between the HCC group and the non-HCC group according to KIR3DL1 + HLA-Bw4 positivity (60.6% vs. 39.4%; \( p = 0.181 \)) or negativity (50.9% vs. 38.5%; \( p = 0.693 \)).

Table 3. Frequency of killer cell immunoglobulin-like receptor (KIR)–HLA pairs in patients with and without hepatocellular carcinoma (HCC).

| Genetic Factor | Patients with HCC (n = 147) | Patients without HCC (n = 64) | Odds Ratio | 95% Confidence Interval | \( p \)-Value |
|----------------|-----------------------------|-------------------------------|------------|-------------------------|-------------|
| KIR2DL1 + HLA-C2 | 19 (12.9)                   | 8 (12.5)                      | 1.04       | 0.43–2.51               | 0.932       |
| KIR2DS1 + HLA-C2 | 9 (6.1)                     | 5 (7.8)                       | 0.77       | 0.25–2.39               | 0.650       |
| KIR2DL2 + HLA-C1 | 24 (16.3)                   | 7 (10.9)                      | 1.59       | 0.65–3.90               | 0.309       |
| KIR2DL3 + HLA-C1 | 145 (98.6)                  | 64 (100.0)                    | -          | -                       | 0.869       |
| KIR2DS2 + HLA-C1 | 22 (15.0)                   | 8 (12.5)                      | 1.23       | 0.52–2.94               | 0.637       |
| KIR3DL1 + HLA-Bw4 | 112 (76.2)                  | 39 (60.9)                     | 2.05       | 1.09–3.85               | 0.024       |
| KIR3DL1 + HLA-Bw4-80I | 94 (63.9)                   | 31 (48.4)                     | 1.89       | 1.04–3.42               | 0.035       |
| KIR3DL1 + HLA-Bw4-80T | 30 (20.4)                   | 12 (18.8)                     | 1.11       | 0.53–2.34               | 0.782       |

Parameters are presented as the total number (%).

2.3. Risk Factors for HCC Development in HCV-Induced Cirrhosis Patients

Multivariate Cox proportional hazards modeling was performed to identify risk factors for developing HCC. The AFP cut-off value was determined as 5.6 ng/mL using Youden’s index. Multivariate analysis revealed the factors of male gender (hazard ratio (HR)—1.56, 95% CI—1.12–2.17; \( p = 0.009 \)), AFP > 5.6 ng/mL (HR—1.56, 95% CI—1.10–2.20; \( p = 0.011 \)), and KIR3DL1 + HLA-Bw4 (HR—1.69, 95% CI—1.15–2.48; \( p = 0.007 \)) as independent risk factors for HCC development (Table 4). Kaplan–Meier analysis showed the cumulative incidence of HCC to be significantly higher in patients with KIR3DL1 + HLA-Bw4 positivity than in KIR3DL1 + HLA-Bw4-negative patients (log-rank test; \( p = 0.013 \)) (Figure 1).

Figure 1. Cumulative incidence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-induced cirrhotic patients according to KIR3DL1 + HLA-Bw4. \( p \)-value was calculated by the log-rank test.
Table 4. Factors associated with HCC development in patients with cirrhosis.

| Factor                             | HR  | 95% CI       | p-Value |
|------------------------------------|-----|--------------|---------|
| Sex, female vs. male              | 1.56| 1.12–2.17    | 0.009   |
| AFP (ng/mL), ≤5.6 vs. > 5.6       | 1.56| 1.10–2.20    | 0.011   |
| KIR3DL1 + HLA-Bw4, negative vs. positive | 1.69| 1.15–2.48    | 0.007   |

Cox proportional hazards model.

We next divided the patients into three groups according to the number of risk factors identified by multivariate analysis (male, AFP > 5.6 ng/mL, and KIR3DL1 + HLA-Bw4 positive). Patients with all three risk factors were assigned to the high-risk group, those with one or two factors to the intermediate risk group, and those with no factors to the low-risk group. Kaplan–Meier testing showed that the cumulative incidence of HCC was highest in the high-risk group, followed next by the intermediate and low-risk groups (log-rank test; p < 0.0001) (Figure 2).

Figure 2. Cumulative incidence of HCC in HCV-induced cirrhotic patients according to the number of the risk factors (male gender, AFP > 5.6 ng/mL, and KIR3DL1 + HLA-Bw4). p-value was calculated by the log-rank test. AFP: α-fetoprotein.

3. Discussion

This single-center retrospective study examined whether specific KIR–HLA pairs played a role in the development of HCC in a cohort of 211 patients with HCV-induced cirrhosis who were followed for a median of 6.6 years. Our results indicated that patients with KIR3DL1 + HLA-Bw4 had a significantly increased risk of HCC onset in Cox regression and Kaplan–Meier analyses. Since the frequency of activating KIR–HLA pairs did not differ significantly between the HCC and non-HCC groups, the inhibitory KIR3DL1+HLA-Bw4 pair, which showed a high and significantly greater frequency in the HCC group, might have contributed to HCC onset by escaping immune surveillance and other intrahepatic inflammatory processes.

Recently, Mele et al. showed that KIR haplotypes were associated with differing abilities of NK cells in HCV-infected patients [18]. Functional impairment in haplotype B carriers was evident from the presence of KIR3DL1 + HLA-Bw4 in HCV-infected subjects, and in haplotype A carriers, increased cytolytic activity was associated with higher STAT1
phosphorylation. Accordingly, we tested the frequencies of genotype A/A and genotype B/x between the HCC and non-HCC groups and in relation to KIR3DL1 + HLA-Bw4 positivity or negativity, although no significant associations were observed between genotype and KIR3DL1 + HLA-Bw4 status. Additional functional analyses of NK cells are needed to clarify the relationship between genotype and KIR3DL1 + HLA-Bw4 in HCV-associated HCC patients.

Our results showed the frequencies of HLA-Bw4 and KIR3DL1 + HLA-Bw4 in the HCC group to be 78.9% and 76.2%, respectively. Since KIR3DL1 positivity was 94.7% in HCV-associated cirrhosis in our cohort, it was difficult to conclusively ascertain HLA-Bw4 or KIR3DL1 + HLA-Bw4 as risk factors for HCC development. Moreover, Kaplan–Meier analysis showed the cumulative incidence of HCC to be significantly higher in patients with HLA-Bw4 positivity and KIR3DL1 + HLA-Bw4 positivity (log-rank test; \( p = 0.026 \) and \( p = 0.013 \), respectively). Previous studies have reported that HLA class I was associated with HCC [19–23]. Therefore, HLA-Bw4 may be implicated with HCC onset due to one or several HLA variants coding for molecules that affect T-cell responses [24]. In multivariate Cox regression analysis, male gender and AFP > 5.6 ng/mL were independent risk factors for the onset of HCC in addition to KIR3DL1 + HLA-Bw4 positivity, but not HLA-Bw4. The 5- and 10-year cumulative incidence rates of HCC were 43.5% and 88.0% in the high-risk group with all three factors, 21.9% and 60.7% in the intermediate-risk group with one or two factors, and 7.7% and 47.6% in the low-risk group with no factors, respectively. Thus, patients with all three risk factors tended to exhibit a more rapid progression to HCC and should be monitored more closely.

Given the functional mechanism and extensive genomic diversity of KIR and HLA ligands, specific KIR–ligand combinations have been associated with the natural clearance of HCV infection and antiviral treatment outcome in patients with chronic hepatitis C [25–32]. KIR–HLA pairs might influence disease progression as well; in our recent examination of KIR–HLA pairs in patients with autoimmune hepatitis, KIR3DL1+HLA-Bw4 was significantly related to a favorable outcome [33]. In fact, the combination of KIR3DS1 and HLA-Bw4 or HLA-Bw4-80I was under-represented in HCC patients as compared with HCV carriers without HCC in Spain and Italy [16,17]. However, our data do not confirm those results.

There are several limitations to this retrospective study. As the numbers of patients with HCC and non-HCC were too small for a definitive conclusion, a larger validation analysis with more subjects is needed to validate our results. Recent direct-acting antiviral therapies have achieved an SVR rate greater than 95% in patients with chronic hepatitis C [34,35]. Although such treatments reduce the risk of HCC development, post-SVR patients remain at an elevated risk of HCC. Since multiple genetic factors have been associated with HCC after an SVR [36,37], additional study is needed to assess whether KIR–HLA pairs are associated with HCC development after an SVR. Furthermore, HLA and KIR are very diverse and complex genes. It will be necessary to analyze those at the allele level using the latest next-generation sequencing methods. Although this study did not employ such techniques and thus could not preclude the possibility of false positives and negatives, the results of 100 control cases were consistent with those measured by the PCR–SSO method. Future studies that include allele typing are being planned. Lastly, KIR3DL1 polymorphisms are known to modulate NK-cell effector function, and the interactions of 3DL1 polymorphisms with their cognate ligands differ in their capacity to inhibit NK cell activity. This inhibitory potential is increased with the level and frequency of 3DL1 expression-encoded high-expression allotypes (KIR3DL1-h), low-expression allotypes (KIR3DL1-l), and no cell surface expression (KIR3DL1-n) [38–40]. The allotypic differences in the frequency and level of KIR3DL1 expression in affecting NK cell function were not investigated in this study. The next step is to explore the allelic level of KIR3DL1 in the development of HCC in HCV-induced cirrhotic patients.
4. Materials and Methods

4.1. Study Population and HCC Surveillance

We considered all patients consecutively referred to Shinshu University Hospital for the diagnosis and management of cirrhosis between January 1991 and December 2013 and who met the following criteria: (1) chronic HCV infection defined by positive serum HCV RNA; (2) cirrhosis proven histologically (n = 165) or by imaging studies (n = 53); (3) no infection of hepatitis B virus or human immunodeficiency virus; (4) absence of other chronic liver disease; (5) Japanese origin; and (6) no evidence of HCC at enrollment or past history of HCC treatment. After the exclusion of 7 patients who exhibited HCC within 1 year after entry, a total of 211 HCV-induced cirrhotic patients were retrospectively included in this study.

HCC surveillance was performed by examining AFP and/or des-γ-carboxy prothrombin, abdominal ultrasonography, and computed tomography and/or magnetic resonance imaging every 6 months. The diagnosis of HCC was based on imaging characteristics, arterial hypervascularity, and venous or delayed phase washout by contrast-enhanced dynamic computed tomography and/or magnetic resonance imaging when a nodular lesion was detected by ultrasonography or a tumor marker was elevated.

4.2. HLA Class I and KIR Typing

Whole-genomic DNA was extracted from whole-blood samples from all participants using QuickGene-800 assays (Fujifilm, Tokyo, Japan). HLA-A typing was carried out using a Luminex multi-analyzer profiling system with a LABType SSO typing kit (One Lambda, Inc., Canoga Park, CA, USA). Since HLA-A*23:01, HLA-A*24:02, and HLA-A*32:01 are known to be part of the HLA-Bw4 family, HLA-A was measured in this study. As reported in a Japanese population database, only HLA-A*24:02 was found in this study, with 23 or 32 not detected. HLA-Bw4, HLA-C1, and HLA-C2 [41] as well as KIR genes [42] were typed using the polymerase chain reaction with sequence-specific primers. HLA typing and KIR typing were used to stratify patients into groups according to predicted KIR–ligand interactions and binding affinities. The KIR–HLA pairs of interest were KIR2DL1+2DS1-HLA-C2, 2DL2/3/2DS2+HLA-C1, and 3DL1+HLA-Bw4. All testing was blinded to the clinical variables. The KIR genotype profiles were assigned to the A/A or B/x genotypes as defined previously [43].

4.3. Statistical Analysis

Continuous variables were compared using the Mann–Whitney U test and categorical variables were evaluated by Pearson’s chi-squared test or Fisher’s exact test, as appropriate. Receiver operating characteristic curve analysis was performed for AFP, and the area under the curve was calculated to evaluate the optimal cut-off value by Youden’s index.

The risk factors associated with the cumulative incidence of HCC were analyzed using a multivariate Cox proportional hazards model. All clinical variables included in the model were assessed at baseline. Multivariate analysis included all significant (p < 0.05) variables in the preceding univariate analysis. The Kaplan–Meier method and log-rank test were employed to assess the cumulative incidence of HCC. Follow-up time was censored on the date of HCC diagnosis and at the end of follow-up (31 December 2020). A p-value of <0.05 was considered statistically significant after Bonferroni correction for multiple testing. Statistical analyses were performed using IBM SPSS Statistics version 27 software (IBM, Tokyo, Japan).

5. Conclusions

In addition to HLA-Bw4, KIR3DL1+HLA-Bw4 is a novel KIR gene and KIR ligand pair that may be associated with the development of HCC in HCV-induced cirrhosis. HCV-associated cirrhotic patients with the risk factors of male gender, AFP > 5.6 ng/mL, and KIR3DL1 + HLA-Bw4 may require careful surveillance for HCC onset.
Author Contributions: Conceptualization, T.U. and M.O.; methodology, T.U.; formal analysis, T.U.; investigation, H.S.; resources, S.J., S.-i.W., H.K., Y.Y., A.S., and T.Y.; writing—original draft preparation, T.U.; writing—review and editing, S.J. and M.O.; visualization, T.U.; supervision, T.U. and M.O.; project administration, T.U. and M.O.; funding acquisition, T.U. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by JSPS grant-in-aid number 20K08282.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Ethics Committee of Shinshu University School of Medicine (protocol codes 302, approved on 10 October 2010, and 527, approved on 10 August 2015).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The datasets used in this study are available from the corresponding author upon a reasonable request.

Acknowledgments: The authors thank Yuki Akahane and Asami Yamazaki for their technical assistance and Trevor Ralph for his English editorial assistance.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Kiyosawa, K.; Sodeyama, T.; Tanaka, E.; Gibo, Y.; Yoshizawa, K.; Nakano, Y.; Furuta, S.; Akahane, Y.; Nishioka, K.; Purcell, R.H.; et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. *Hepatology* 1990, 12, 671–675. [CrossRef] [PubMed]
2. Villanueva, A. Hepatocellular Carcinoma. *New Engl. J. Med.* 2019, 380, 1450–1462. [CrossRef]
3. Umemura, T.; Ichijo, T.; Yoshizawa, K.; Tanaka, E.; Kiyosawa, K. Epidemiology of hepatocellular carcinoma in Japan. *J. Gastroenterol.* 2009, 44 (Suppl. 19), 102–107. [CrossRef] [PubMed]
4. Singal, A.G.; Lampertico, P.; Nahon, P. Epidemiology and surveillance for hepatocellular carcinoma: New trends. *J. Hepatol.* 2020, 72, 250–261. [CrossRef]
5. Tateishi, R.; Uchino, K.; Fujiwara, N.; Takehara, T.; Okanoue, T.; Seike, M.; Yoshiji, H.; Yatsuhashi, H.; Shimizu, M.; Torimura, T.; et al. A nationwide survey on non-b, non-C hepatocellular carcinoma in Japan: 2011-2015 update. *J. Gastroenterol.* 2019, 54, 367–376. [CrossRef] [PubMed]
6. Muller, M.; Bird, T.G.; Nault, J.C. The landscape of gene mutations in cirrhosis and hepatocellular carcinoma. *J. Hepatol.* 2020, 72, 990–1002. [CrossRef]
7. Caruso, S.; O’Brien, D.R.; Cleary, S.P.; Roberts, L.R.; Zucman-Rossi, J. Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. *Hepatology*. 2021, 73 (Suppl. S1), 14–26. [CrossRef]
8. Vivier, E.; Tomasello, E.; Baratin, M.; Walzer, T.; Ugolini, S. Functions of natural killer cells. *Nat. Immunol.* 2008, 9, 503–510. [CrossRef]
9. Martinet, L.; Smyth, M.J. Balancing natural killer cell activation through paired receptors. *Nat. Rev. Immunol.* 2015, 15, 243–254. [CrossRef]
10. Farhman, P. MHC class I molecules and KIRs in human history, health and survival. *Nat. Rev. Immunol.* 2005, 5, 201–214. [CrossRef]
11. Colonna, M.; Borsellino, G.; Falco, M.; Ferrara, G.B.; Strominger, J.L. HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells. *Proc. Natl. Acad. Sci. USA* 1993, 90, 12000–12004. [CrossRef]
12. Cella, M.; Longo, A.; Ferrara, G.B.; Strominger, J.L.; Colonna, M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. *J. Exp. Med.* 1994, 180, 1225–1242. [CrossRef] [PubMed]
13. Naumova, E.; Mihaylova, A.; Stoitchkov, K.; Ivanova, M.; Quin, L.; Toneva, M. Genetic polymorphism of NK receptors and their ligands in melanoma patients: Prevalence of inhibitory over activating signals. *Cancer Immunol. Immunother.* 2005, 54, 172–178. [CrossRef] [PubMed]
14. Naumova, E.; Mihaylova, A.; Ivanova, M.; Mihailova, S. Impact of KIR/HLA ligand combinations on immune responses in malignant melanoma. *Cancer Immunol. Immunother.* 2007, 56, 95–100. [CrossRef] [PubMed]
15. Saito, H.; Umemura, T.; Yoshizawa, K.; Fujimori, N.; Kimura, T.; Komatsu, M.; Matsumoto, A.; Tanaka, E.; Ota, M. KIR2DL2 combined with HLA-C1 confers risk of hepatitis C virus-related hepatocellular carcinoma in younger patients. *Onco Targets Ther.* 2018, 9, 19650–19661. [CrossRef]
16. Lopez-Vazquez, A.; Rodrigo, L.; Martinez-Borras, J.; Perez, R.; Rodriguez, M.; Fdez-Morera, J.L.; Fuentes, D.; Rodriguez-Rodero, S.; Gonzalez, S.; Lopez-Larrea, C. Protective effect of the HLA-Bw480 epitope and the killer cell immunoglobulin-like receptor 3DSi gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection. *J. Infect. Dis.* 2005, 192, 162–165. [CrossRef] [PubMed]
17. De Re, V.; Caggiari, L.; de Zorzi, M.; Repetto, O.; Zignego, A.L.; Izzo, F.; Tornesello, M.L.; Buonaguro, F.M.; Mangia, A.; Sansonno, D.; et al. Genetic diversity of the KIR/HLA system and susceptibility to hepatitis C virus-related diseases. *PLoS ONE* 2015, 10, e0117420. [CrossRef] [PubMed]
18. Mele, D.; Pasi, A.; Cacciatorre, R.; Mantovani, S.; Oliviero, B.; Mondelli, M.U.; Varchetta, S. Decreased interferon-gamma production by NK cells from KIR haplotype B carriers in hepatitis C virus infection. *Liver Int.* **2019**, *39*, 1237–1245. [CrossRef]

19. Sawai, H.; Nishida, N.; Khor, S.S.; Honda, M.; Sugiyama, M.; Baba, N.; Yamada, K.; Sawada, N.; Tsugane, S.; Koike, K.; et al. Genome-wide association study identified new susceptible genetic variants in HLA class I region for hepatitis B virus-related hepatocellular carcinoma. *Sci. Rep.* **2018**, *8*, 7958. [CrossRef]

20. Matsuura, K.; Tanaka, Y. Host genetic variants influencing the clinical course of hepatitis C virus infection. *J. Med. Virol.* **2016**, *88*, 185–195. [CrossRef]

21. Tseng, K.C.; Tseng, C.W.; Hsieh, Y.H.; Chang, C.K.; Lai, N.S.; Hung, T.H.; Chang, T.T. Effect of human leukocyte antigen class I and II alleles on hepatitis C viral load among chronic hepatitis C patients in Southern Taiwan. *Hum. Immunol.* **2013**, *74*, 978–982. [CrossRef] [PubMed]

22. Singh, R.; Kaul, R.; Kaul, A.; Khan, K. A comparative review of HLA associations with hepatitis B and C viral infections across global populations. *World J. Gastroenterol.* **2007**, *13*, 1770–1787. [CrossRef] [PubMed]

23. Golubovic, G.; Stajic, M.; Stolic, I.; Nikolic, J.A.; Neskovic, A.N.; Pandey, L. Histocompatibility antigens in patients with hepatocellular carcinoma. *Z Gastroenterol.* **1996**, *34*, 15–20. [PubMed]

24. Hofmann, M.; Tauber, C.; Hensel, N.; Thimme, R. CD8+ T Cell Responses during HCV Infection and HCC. *J. Viral Hepat.* **2018**, *25*, 1168–1175. [CrossRef]

25. Khakoo, S.I.; Thio, C.L.; Martin, M.P.; Brooks, C.R.; Gao, X.; Astemborski, J.; Cheng, J.; Goedert, J.J.; Vlahov, D.; Hilgarter, M.; et al. HLA and NK cell inhibitory receptor polymorphism in resolving hepatitis C virus infection. *Science* **2004**, *305*, 872–874. [CrossRef]

26. Knapp, S.; Warshow, U.; Hegazy, D.; Brackenbury, L.; Guha, I.N.; Fowell, A.; Little, A.M.; Alexander, G.J.; Rosenberg, W.M.; Cramp, M.E.; et al. Consistent beneficial effects of killer cell immunoglobulin-like receptor 2DL3 and group 1 human leukocyte antigen-C following exposure to hepatitis C virus. *Hepatology* **2010**, *51*, 1168–1175. [CrossRef]

27. Vidal-Castineira, J.R.; Lopez-Vazquez, A.; Diaz-Pena, R.; Alonso-Arias, R.; Martinez-Borra, J.; Perez, R.; Fernandez-Suarez, J.; Melon, S.; Prieto, J.; Rodrigo, L.; et al. Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection. *J. Virol.* **2010**, *84*, 475–481. [CrossRef]

28. Suppiah, V.; Gaudieri, S.; Armstrong, N.J.; O'Connor, K.S.; Berg, T.; Weltman, M.; Abate, M.L.; Spengler, U.; Bassendine, M.; Dore, G.J.; et al. IL28B, HLA-C, and KIR variants additively predict response to therapy in chronic hepatitis C virus infection in a European Cohort: A cross-sectional study. *PLoS Med.* **2011**, *8*, e1000192. [CrossRef]

29. Dring, M.M.; Morrison, M.H.; McSharry, B.P.; Guinan, K.J.; Hagan, R.; O'Farrelly, C.; Gardiner, C.M. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 5736–5741. [CrossRef]

30. Nozawa, Y.; Umemura, T.; Joshi, S.; Katsuyama, Y.; Shibata, S.; Kimura, T.; Morita, S.; Komatsu, M.; Matsumoto, A.; Tanaka, E.; et al. KIR, HLA, and IL28B Variant Predict Response to Antiviral Therapy in Genotype 1 Chronic Hepatitis C Patients in Japan. *PloS ONE* **2013**, *8*, e83381. [CrossRef]

31. Fitzmaurice, K.; Hurst, J.; Dring, M.; Rauch, A.; McLaren, P.J.; Gunthard, H.F.; Gardiner, C.; Klenerman, P.; Irish HCV Research Consortium; Swiss HIV Cohort Study. Additive effects of HLA alleles and innate immune genes determine viral outcome in HCV infection. *Gut* **2015**, *64*, 813–819. [CrossRef]

32. Thons, C.; Senff, T.; Hydes, T.J.; Manser, A.R.; Heinemann, F.M.; Heinold, A.; Heilmann, M.; Kim, A.Y.; Uhrberg, M.; Scherbaum, N.; et al. HLA-Bw4 80(T) and multiple HLA-Bw4 copies combined with KIR3DL1 associate with spontaneous clearance of HCV infection in people who inject drugs. *J. Hepatol.* **2017**, *66*, 472–477. [CrossRef]

33. Umemura, T.; Joshi, S.; Saito, H.; Yoshizawa, K.; Norman, G.L.; Tanaka, E.; Ota, M. KIR/HLA genotypes confer susceptibility and progression in patients with autoimmune hepatitis. *JHEP Rep.* **2019**, *1*, 353–360. [CrossRef] [PubMed]

34. Sugiuira, A.; Joshi, S.; Umemura, T.; Yamazaki, T.; Fujimori, N.; Kimura, T.; Matsumoto, A.; Igarashi, K.; Usami, Y.; Wada, S.; et al. Past history of hepatocellular carcinoma is an independent risk factor of treatment failure in patients with chronic hepatitis C virus infection receiving direct-acting antivirals. *J. Viral Hepat.* **2018**, *25*, 1462–1471. [CrossRef] [PubMed]

35. Sugiuira, A.; Joshi, S.; Yamashita, Y.; Fujimori, T.; Kimura, T.; Matsumoto, A.; Wada, S.; Mori, H.; Shibata, S.; et al. Effectiveness of Glecaprevir/Pibrentasvir for Hepatitis C: Real-World Experience and Clinical Features of Retreatment Cases. *Cancers* **2020**, *12*, 348. [CrossRef]

36. Ito, E.; Matsuura, K.; Shimada, N.; Atsukawa, M.; Itoikawa, N.; Abe, H.; Kato, K.; Takaguchi, K.; Senoh, T.; Eguchi, Y.; et al. TLR1 variant associated with development of hepatocellular carcinoma after eradication of hepatitis C virus by interferon-free therapy. *J. Gastroenterol.* **2019**, *54*, 339–346. [CrossRef]

37. Miki, D.; Akita, T.; Kurisu, T.; Kawaoaka, T.; Nakajima, T.; Hige, S.; Karino, Y.; Toyoda, H.; Kumada, T.; Tsuge, M.; et al. PNPLA3 and HLA-DQB1 polymorphisms are associated with hepatocellular carcinoma after hepatitis C virus eradication. *J. Gastroenterol.* **2020**, *55*, 1162–1170. [PubMed]

38. Gardiner, C.M.; Guethlein, L.A.; Shilling, H.G.; Pando, M.; Carr, W.H.; Rajalingam, R.; Vilches, C.; Parham, P. Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. *J. Immunol.* **2001**, *166*, 2992–3001. [CrossRef]

39. Yawata, M.; Yawata, N.; Draghi, M.; Little, A.M.; Partheniou, F.; Parham, P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. *J. Exp. Med.* **2006**, *203*, 633–645. [CrossRef]
40. Trundley, A.; Frebel, H.; Jones, D.; Chang, C.; Trowsdale, J. Allelic expression patterns of KIR3DS1 and 3DL1 using the Z27 and DX9 antibodies. *Eur. J. Immunol.* 2007, *37*, 780–787. [CrossRef]

41. Tajik, N.; Shahsavar, F.; Nasiri, M.; Radjabzadeh, M.F. Compound KIR-HLA genotype analyses in the Iranian population by a novel PCR-SSP assay. *Int. J. Immunogenet.* 2010, *37*, 159–168. [CrossRef] [PubMed]

42. Vilches, C.; Castano, J.; Gomez-Lozano, N.; Estefania, E. Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. *Tissue Antigens* 2007, *70*, 415–422. [CrossRef] [PubMed]

43. Cooley, S.; Trachtenberg, E.; Bergemann, T.L.; Saeuern, K.; Klein, J.; Le, C.T.; Marsh, S.G.; Guethlein, L.A.; Parham, P.; Miller, J.S.; et al. Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia. *Blood* 2009, *113*, 726–732. [CrossRef] [PubMed]